Cargando…
Anti-Proliferative Activity of HPOB against Multiple Myeloma Cells via p21 Transcriptional Activation
Histone acetylation or deacetylation is closely associated with the progression of multiple myeloma (MM). Currently, many histone deacetylase (HDAC) inhibitors have been approved for being used in clinical trials, but theirtherapeutic effectsarestill not ideal. As a novel HDAC inhibitor, hydroxamica...
Autores principales: | Liu, Linlin, Sun, Xiaoyang, Xie, Yu, Zhuang, Yinping, Yao, Ruosi, Xu, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100322/ https://www.ncbi.nlm.nih.gov/pubmed/29710846 http://dx.doi.org/10.3390/molecules23051044 |
Ejemplares similares
-
Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
por: Liu, Linlin, et al.
Publicado: (2018) -
Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma
por: Yao, Ruosi, et al.
Publicado: (2020) -
Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells
por: Yao, Ruosi, et al.
Publicado: (2018) -
The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
por: Sun, Xiaoyang, et al.
Publicado: (2019) -
Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments
por: Zhou, Jian, et al.
Publicado: (2021)